Genzyme, a subsidiary of Sanofi, announced that following constructive discussions with the US Food and Drug Administration (FDA) the company plans to resubmit in the second quarter its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.  The resubmission will provide information to specifically address issues noted by the FDA in its December 27, 2013 Complete Response Letter.

Genzyme had previously announced its intention to appeal the FDA's Complete Response Letter.  In light of the planned resubmission, the company does not expect to pursue an appeal at this time.

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. Genzyme holds the worldwide rights to alemtuzumab and has primary responsibility for its development and commercialization in multiple sclerosis. Bayer HealthCare holds the right to co-promote alemtuzumab in MS in the United States. Upon commercialization, Bayer will receive contingent payments based on global sales revenue.

Genzyme is a registered trademark and Lemtrada is a trademark of Genzyme Corporation.